Wesley Armstrong, BS, UCLA, Los Angeles, CA, discusses the potential implementation of PSMA PET/CT for informing treatment management for patients with prostate cancer. Further data is expected on survival outcomes from a Phase III trial (NCT03582774) investigating the impact of PSMA PET/CT on salvage radiotherapy planning for prostate cancer patients. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
